Three photoaffinity ligands (PALs) for the human serotonin transporter (hSERT) were synthesized based on the selective serotonin reuptake inhibitor (SSRI), (S)citalopram (1). The classic 4-azido-3-iodo-phenyl group was appended to either the C-1 or C-5 position of the parent molecule, with variable-length linkers, to generate ligands 15, 22, and 26. These ligands retained high to moderate affinity binding (K i = 24−227 nM) for hSERT, as assessed by [ 3 H]5-HT transport inhibition. When tested against Ser438Thr hSERT, all three PALs showed dramatic rightward shifts in inhibitory potency, with K i values ranging from 3.8 to 9.9 μM, consistent with the role of Ser438 as a key residue for highaffinity binding of many SSRIs, including (S)-citalopram. Photoactivation studies demonstrated irreversible adduction to hSERT by all ligands, but the reduced (S)-citalopram inhibition of labeling by [ 125 I]15 compared to that by [ 125 I]22 and [ 125 I]26 suggests differences in binding mode(s). These radioligands will be useful for characterizing the drug−protein binding interactions for (S)-citalopram at hSERT.
■ INTRODUCTION
The serotonin transporter (SERT) is a member of the solute carrier 6 (SLC6) family of transporters that functions to regulate serotonin neurotransmission and homeostasis. 1−3 In particular, selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), widely prescribed medications for treatment of anxiety and major depressive disorders, principally work by binding to SERT and inhibiting serotonin reuptake into presynaptic neurons. 4, 5 Notably, (S)-citalopram (1, Escitalopram, Figure 1 ) binds with high affinity and selectivity to hSERT. However, despite its well-documented clinical success, the molecular interactions between (S)citalopram and hSERT that determine its reuptake inhibition potency and selectivity over the norepinephrine transporter (NET) and dopamine transporter (DAT) remain poorly understood.
The 3D structure of SERT as well as its structure, function, and regulation, including oligomerization and distribution in cells or brain tissue, has been studied with small molecular probes containing electrophiles (e.g., N 3 , NCS) and radiolabels (e.g., 3 H, 125 I). In particular, the well-known technique of photoaffinity labeling utilizes molecular probes that contain a functional group capable of forming a covalent bond to a biological target upon photoactivation. 6, 7 Of the numerous photoreactive functional groups that can be employed in the design of photoaffinity ligands (PALs) (e.g., benzophenones, aliphatic and aromatic diazirines, etc.), aryl azides are frequently used given their relatively small size, ease of synthetic incorporation, and chemical stability. 8 Numerous [ 125 I]-radiolabeled-arylazido analogues of dopamine transporter (DAT) inhibitors including cocaine, 9−12 GBR12909 (1- [2- [bis(4-fluorophenyl)methoxy]ethyl]-4-(3phenylpropyl)piperazine), 13−16 benztropine, 10, 17, 18 pyrovaler-one, 19 bupropion, 20 and methylphenidate 21, 22 have been developed to elucidate molecular components of the ligandbinding site and mechanisms underlying uptake inhibition. The 4′-azido, 3′-iodo-substituted phenyl ring is a common structural motif found in many PALs that bind DAT irreversibly upon photoactivation (e.g., RTI 82 (2) , , and JHC 2-48 (4); Figure 1 ). 9−12 Specifically, tropane-based PALs 2 and 3 have been instrumental in defining drug−protein interactions at the molecular level and thus further defining the structural components of DAT that are critical for transport inhibition by cocaine. 23−25 In contrast to DAT PALs, the development of SERTselective PALs has been more limited. To the best of our knowledge, only a few PALs have been synthesized and experimentally validated to label SERT (Figure 1) . Although tropane-based PALs 2−4 bind to SERT as well as DAT, to date, only probes 3 and 4 have been used to photolabel hSERT. 12, 26 Other inhibitor-based ligands that photolabel SERT include an aryl-azido derivative of the SSRI paroxetine (5) 27 and a tricyclic antidepressant-based PAL, [ 3 H]-2nitroimipramine (6) , that showed covalent incorporation into SERT present in membrane homogenates of rat brain and liver and human platelets. 28, 29 Finally, photoinactivation of serotonin uptake has been demonstrated by an azidobenzamidine derivative of serotonin (7) . 30 However, to date, none of these SERT PALs have been used to define the structural basis of their binding interactions at hSERT.
On the basis of successful application of PALs 2−4 in elucidating drug−binding site interactions at DAT, 23−25 our concept for the present study was that appending the 4′-azido, 3′-iodo aryl moiety onto different positions of the (S)citalopram base might reveal different sites of adduction on hSERT that would enable a clearer understanding of the (S)citalopram binding mechanism. Extensive structure−activity relationships have been described with analogues of citalopram that suggest positions C-1 and C-5 can accommodate significant steric bulk without appreciable loss in hSERT binding affinity. 31−34 Herein, we describe the design, synthesis, pharmacological evaluation, and radiosynthesis of three novel C-1-or C-5-substituted 4′-azido, 3′-iodo analogues of (S)citalopram and demonstrate their ability to covalently label hSERT upon photoactivation.
■ CHEMISTRY
The synthesis of C-1-substituted (S)-citalopram PAL 15 is shown in Scheme 1. Phthalimide derivative 9 35 was synthesized by stirring 2-(4-aminophenyl)ethan-1-ol (8) with phthalic anhydride in pyridine, at reflux, and oxidizing to aldehyde 10 using a Dess−Martin periodinane reagent. 36 ,37 (S)-N-Desme-thylcitalopram (11) 31, 32 was then coupled to aldehyde 10 using standard reductive amination conditions to provide tertiary amine 12 in 80% yield, followed by phthalimide deprotection to give aniline 13. Iodination with iodine monochloride (ICl) gave the intermediate 14, which was then treated with NaNO 2 followed by NaN 3 to give 4′-azido, 3′-iodo product 15.
The synthesis of C-5-substituted (S)-citalopram PALs 22 and 26 is shown in Scheme 2. 3-(4-Aminophenyl)propanoic acid (16) was initially stirred at reflux with phthalic anhydride to afford the corresponding phthalimide carboxylic acid 17. 38 Subsequent coupling of 17 to primary amine 18 31,32 via the acid chloride provided amide 19 in 97% yield. Deprotection of 19 using hydrazine provided aniline intermediate 20, which was reacted with ICl to give 3′-iodo-substituted product 21. Conversion to azido PAL 22 was then performed as previously described for 15 via diazotization and azide displacement of aniline 21. This final step went in poor yield (18%); thus, a second strategy was also developed that featured a decrease in the number of synthetic steps and an increase in the overall yield. This alternative strategy began with electrophilic iodination of aniline 16 ortho to the amine to provide the corresponding iodo-substituted aniline 23 in 67% yield, which was subsequently treated with NaNO 2 followed by NaN 3 in TFA to give iodo-azide 24. 39 Primary amine 18 was then coupled to azido-iodo carboxylic acid 24 using 1,1′-carbonyldiimidazole (CDI) in THF to generate amide 22. Although this route using 24 is preferred for generating nonradioactive 22 in high yield, the initial route that provided 20 was utilized in the synthesis of [ 125 I]-labeled 22. Similarly, 18 was coupled to 4-azido-3-iodobenzoic acid 40 (25) 22 . This sequence was accomplished in one flask, as previously described for other radioiodinated PALs. 11, 41, 42 Electrophilic radioiododestannylation of tri-n-butylstannyl azide 27 using chloramine-T as the oxidant in methanolic acetic acid for 3 min was employed to prepare [ 125 I] 26 . The organostannane precursor was obtained in 52% yield by treating nonradioactive iodide 26 with bis(tri-n-butyltin) and bis(triphenylphosphine)palladium(II) dibromide. Since carryover of trace amounts of 26 would dramatically lower the specific radioactivity of [ 125 I]26 prepared from 27, 43 this material was purified by reversed-phase HPLC prior to radiolabeling.
All three radioligands were purified by reversed-phase HPLC and then formulated as concentrated solutions in MeOH using solid-phase extraction. Isolated radiochemical yields were 46− 55%. Specific radioactivities were determined as 2045 to 2098 mCi/μmol, near the theoretical value of 2175 mCi/μmol, using HPLC to determine the mass associated with the UV absorbance peak in samples of known radioactivity. Radio-chemical purities were ≥98% by HPLC ( Figure 2 ), and the materials were stable for at least 5 weeks when stored at −20°C in the dark. The three radioligands proved to be lipophilic, with 
■ RESULTS AND DISCUSSION
Pharmacological Properties of PALs 15, 22, and 26. Inhibition of [ 3 H]5-HT uptake by WT hSERT and the hSERT Ser438Thr mutant was evaluated to determine inhibitory constants for PALs 15, 22, 26 and parent compound (S)citalopram (1). When tested against WT hSERT, C-5substituted PALs 26 and 22 showed affinities of 24 and 38 nM, respectively, values that were reduced by 11-and 17-fold compared to that of (S)-citalopram (K i = 2.2 nM) ( Figure 3 and Table 1 ). In contrast, C-1 substituted PAL 15 showed a greater reduction in affinity (K i = 227 nM, 100-fold) compared to that of (S)-citalopram, which is in accord with structure− activity relationships previously described. 32 When tested against the hSERT Ser438Thr mutant, all four compounds showed dramatic rightward shifts in inhibitory potency ( Figure  3 , dashed lines) with K i values ranging from 3.8 to 9.9 μM (Table 1) . These findings are consistent with previous reports that Ser438 is a key residue for high-affinity binding of many hSERT antagonists and that its mutation to Thr results in a significant loss in potency for (S)-citalopram and many other hSERT inhibitors. 44 demonstrated lower affinity than (S)-citalopram or the other PALs for WT hSERT but higher affinity for the S438T mutant. Moreover, the difference in binding affinities between the mutant and WT hSERT for 15 was only 17-fold, as compared to a more dramatic shift for parent ligand 1 (∼3600-fold).
Photoaffinity 26 for irreversible labeling of HA-hSERT ( Figure 4 ). For these studies, HA-hSERT LLCPK 1 cells were incubated with the PALs in the presence or absence of (S)-citalopram and irradiated with UV light to cross-link the ligand to the protein. Lysates were immunoprecipitated with anti-HA or anti-hSERT antibodies, and samples were analyzed by SDS-PAGE and autoradiography. These methods (described in detail in the Experimental Methods) have been used by our laboratories to verify photolabeling of DAT and SERT by numerous structurally diverse tropane-and non-tropane-based ligands. 11,12,17,19−26 The results ( Figure 4) 26 all covalently label a protein of the expected hSERT molecular mass of ∼100 kDa, whereas photolabeled bands were not obtained from nontransfected parent cells (upper panels), strongly supporting the identity of the photolabeled bands as hSERT. Immunoblotting (lower panels) verified the presence and absence of hSERT protein in transfected and untransfected cells, respectively. The photoaffinity labeled proteins were immunoprecipitated using anti-HA antibody ( Figure 4 ) as well as with the anti-hSERT antibody ST51 (not shown), but they were not precipitated with nonimmune IgG (not shown), also supporting the identity of the bands as hSERT. Similar irreversible labeling and immunoprecipitation results were obtained using tropane PAL 3, which was previously demonstrated to photolabel hSERT. 26 Together, these results demonstrate that hSERT protein is irreversibly labeled with [ 125 I]15, [ 125 I] 22 , and [ 125 I]26 upon photoactivation, providing the first demonstration of photoaffinity labeling of hSERT by analogues of (S)-citalopram.
For pharmacological characterization of irreversible labeling, HA-hSERT-LLCPK 1 cells were incubated with vehicle or 10 26 was blocked by >99%, demonstrating that (S)-citalopram fully displaces these C-5 substituted radioligands, similar to displacement of hSERT labeling by [ 125 I]3. 26 In contrast, 10 μM (S)-citalopram inhibited [ 125 I]15 labeling of hSERT by only ∼30%, suggesting that this C-1-substituted PAL exhibits a different binding mode compared to that of the two C-5-substituted ligands. In a previous SAR study, wherein (S)-citalopram was modified by N-substitution at the C-5 position with a second molecule of (S)-citalopram to create a homobifunctional ligand, binding data suggested simultaneous interaction of the ligand with the S1 and S2 binding sites. 32 Moreover, the affinity of (S)citalopram for S2 is much lower than that for S1. 45 Thus, it is conceivable that [ 125 I]15 may be binding to both the S1 and S2 sites and that the latter might not be fully inhibited by 10 μM (S)-citalopram. 32, 45 In ■ EXPERIMENTAL METHODS General. Reaction conditions and yields were not optimized. Anhydrous solvents were purchased from Aldrich and were used without further purification, except for tetrahydrofuran, which was freshly distilled from sodium benzophenone ketyl. All other chemicals and reagents were purchased from Sigma-Aldrich Co. LLC, Combi-Blocks, TCI America, Acros Organics, and Alfa Aesar. Unless otherwise stated, final amine products were converted into oxalate salts, typically by treating the free base in CHCl 3 with a 1:1 molar ratio of oxalic acid in acetone. As described, some of the oxalate salts were recrystallized from hot methanol or a methanol−acetone solvent mixture. Flash chromatography was performed using silica gel (EMD Chemicals, Inc., 230−400 mesh, 60 Å). 1 H and 13 C NMR spectra were acquired using a Varian Mercury Plus 400 spectrometer at 400 and 100 MHz, respectively. Chemical shifts are reported in parts per million (ppm) and referenced according to deuterated solvent for 1 H spectra (CDCl 3 , 7.26 ppm, or CD 3 OD-d 4 , 3.31 ppm) and 13 C spectra (CDCl 3 , 77.2 ppm, or CD 3 OD-d 4 , 49.00 ppm). Infrared (IR) spectra were obtained (neat) on a PerkinElmer Spectrum Two FTIR spectrometer. Gas chromatography/mass spectrometry (GC/MS) data were acquired (where obtainable) using an Agilent Technologies (Santa Clara, CA) 6890N gas chromatograph equipped with an HP-5MS column (cross-linked 5% PH ME siloxane, 30 m × 0.25 mm i.d. × 0.25 μm film thickness) and a 5973 mass-selective ion detector in electron-impact mode. Ultrapure grade helium was used as the carrier gas at a flow rate of 1.2 mL/min. The injection port and transfer line temperatures were 250 and 280°C, respectively, and the oven temperature gradient used was as follows: the initial temperature (100°C ) was held for 3 min, increased to 295°C at 15°C/min over 13 min, and finally maintained at 295°C for 10 min. To acquire highresolution mass spectrometry (HRMS) data, 1 μL of sample was mixed with 1 μL of matrix (saturated solution of 2,4,6-trihydroxyacetophenone/2,5-dihydroxybenzoic acid in 50:50 ethanol/water); then, 1 μL was deposited on a stainless steel plate and analyzed in Figure 3 . K i values were calculated using the Cheng−Prusoff equation in GraphPad Prism 5. Data were analyzed by paired t-tests for statistical significance, where * indicates that the K i value obtained with the hSERT S438T mutant is significantly different than the K i of that compound for WT hSERT (p < 0.001) and # indicates that the K i value for the analogue is significantly different than the K i for (S)citalopram obtained with WT hSERT (p < 0.001). The K i values obtained with hSERT S438T for the analogues and (S)-citalopram were not statistically different from one another. (S)-1-(3-((4-Amino-3-iodophenethyl)(methyl)amino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (14) . A 1 M solution of ICl in CH 2 Cl 2 (0.085 g, 0.64 mmol) was added dropwise to a solution of aniline 13 (0.230 g, 0.53 mmol) in CH 2 Cl 2 at 0−5°C. The reaction mixture was allowed to warm to RT and stirred overnight. The reaction mixture was then quenched with 10% aq sodium thiosulfate. The organic layer was collected, dried, concentrated, and purified by flash chromatography using 2:8 acetone/ CHCl 3 to give 0.095 g of iodide 14 (32%). 1 H NMR (400 MHz, (S)-1-(3-((4-Azido-3-iodophenethyl)(methyl)amino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (15) . To a solution of aniline 14 (0.095 g, 0.17 mmol) in TFA (3 mL) was added NaNO 2 (0.023 g, 0.34 mmol) at 0°C, in the dark. The reaction mixture was then stirred for 45 min at 0−5°C. NaN 3 (0.111 g, 1.71 mmol) and anhydrous ether (3 mL) was then added to the reaction mixture, followed by stirring for 1 h at 0−5°C, and the mixture was then diluted with H 2 O and ether (10 mL each). The organic layer was separated, dried, concentrated, and purified by flash chromatography using 3:7 acetone/CHCl 3 to provide 0.086 g of azide 15 as an oil (87%). 1 (19) . A mixture of carboxylic acid 17 38 (0.257 g, 0.87 mmol) and thionyl chloride (2 mL) was stirred at reflux for 3 h and then concentrated in vacuo. The remaining thionyl chloride was removed by azeotropic distillation using benzene. The crude solid was dissolved in the CHCl 3 and added dropwise to a vigorously stirred mixture of amine 18 31,32 (0.395 g, 0.73 mmol), CHCl 3 (10 mL), and 0.5 M aq NaOH (10 mL) at 0°C, followed by stirring for 3 h at RT. The organic layer was separated, dried, and purified by flash chromatography using 6:94 MeOH/CHCl 3 eluent to provide 0.425 g of amide 19 as a white solid (97%), mp 114−115°C. 1 (20) . Hydrazine (0.069 g, 2.15 mmol) was added to a solution of phthalimide 19 (0.425 g, 0.72 mmol) in EtOH (15 mL). The reaction mixture was stirred at reflux for 6 h, concentrated, and diluted with a 30% aq K 2 CO 3 solution. The organic layer was extracted, dried, and purified by flash chromatography using 8:92 MeOH/CHCl 3 to provide 0.301 g of aniline 20 (88%). 1 (S)-3-(4-Amino-3-iodophenyl)-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)methyl)propanamide (21) . A 1.0 M solution of ICl in CH 2 Cl 2 (0.083 g, 0.63 mmol) was added dropwise to a solution of aniline 20 (0.231 g, 0.48 mmol) in CH 2 Cl 2 (15 mL) at 0−5°C over 30 min. The reaction mixture was allowed to warm to RT and stirred overnight. The reaction mixture was then diluted with 10% aq Na 2 S 2 O 3 (25 mL), stirred for 10 min, and extracted in CH 2 Cl 2 . After discarding the aqueous layer, the black residue was dissolved in MeOH and combined with the previous CH 2 Cl 2 solution. The organic layer was concentrated and purified by flash chromatography using 7:93 MeOH/CHCl 3 to provide 0.292 g of iodide 21 as an oil (62%). 1 (S)-3-(4-Azido-3-iodophenyl)-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)methyl)propanamide (22) . Method A. NaNO 2 (9.6 mg, 0.14 mmol) was added to a suspension of aniline 21 (60 mg, 0.10 mmol) in a mixture of glacial HOAc (3 mL) and H 2 O (1 mL) at 0°C, in the dark. The mixture was stirred for 30 min; then, NaN 3 (9.7 mg, 0.15 mmol) was added to the reaction mixture. After stirring at 0−5°C for 30 min, the reaction was diluted with water (10 mL). The mixture was then carefully quenched with saturated aq NaHCO 3 to a pH of 9−10. The crude product was extracted with CHCl 3 , dried over Na 2 SO 4 , concentrated, and purified by preparative TLC using 15:85 MeOH/ CHCl 3 to provide 20 mg of azide 22 as a yellow oil (18%). 1 Method B. CDI (0.064 g, 0.39 mmol) was added to a solution of carboxylic acid 24 39 (0.125 g, 0.39 mmol) in THF (15 mL) under an argon atmosphere. The reaction mixture was stirred for 6 h and then cooled to 0−5°C using an ice bath. Primary amine 18 31,32 (0.129 g, 0.39 mmol) was then added dropwise after dilution with THF (10 mL). The reaction mixture was allowed to warm to RT and stirred overnight, followed by subsequent concentration, dilution with water (20 mL), and extraction with CHCl 3 (2 × 20 mL). The organic layer was dried, concentrated, and purified by flash chromatography using 3:97 MeOH/CHCl 3 as eluent to provide 0.054 g of amide 22 as a yellow oil (22%).
3-(4-Amino-3-iodophenyl)propanoic Acid (23). 39 A 1 M solution of ICl in HOAc (0.240 g, 1.82 mmol) was added dropwise slowly to a solution of 3-(4-aminophenyl)propanoic acid (16, 0.250 g, 1.51 mmol) in glacial HOAc (8 mL) at RT. The reaction mixture was stirred overnight and then quenched with 10% aq Na 2 SO 3 . The crude product was extracted with CH 2 Cl 2 (2 × 20 mL), dried, concentrated, and purified by flash chromatography using 3:97 MeOH/CHCl 3 to provide 0.296 g of acid 23 as a pure white solid (67%).
3-(4-Azido-3-iodophenyl)propanoic Acid (24) . 39 Azide 24 was prepared using the same method as described for azide 22 (Method A) in TFA. The crude product was purified by flash chromatography using 2:98 MeOH/CHCl 3 and used directly in the next step, Method B, to synthesize 22.
(S)-4-Azido-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)methyl)-3-iodobenzamide (26) . To a solution of 4-azido-3-iodobenzoic acid 40 (25, 87 mg, 0.30 mmol) in DMF (2 mL) at 0°C were added EDC (49 mg, 0.31 mmol) and HOBT (43 mg, 0.31 mmol). The resulting mixture was stirred in the dark for 1 h at 0°C. To this mixture were added a solution of 18 31, 32 (99 mg, 0.30 mmol) in DMF (1 mL) and Et 3 N (0.2 mL), followed by stirring in the dark at RT overnight. The mixture was then diluted with H 2 O and extracted with EtOAc. The combined organic extracts were washed with 1 M aq NaOH and brine, dried (MgSO 4 ), filtered, concentrated, and chromatographed using 95:5 EtOAc/Et 3 N to provide 120 mg of amide 26 as a colorless semisolid (67%). 1 
